Axxcess Wealth Management LLC Acquires 330 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Axxcess Wealth Management LLC boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.3% in the third quarter, Holdings Channel reports. The firm owned 10,271 shares of the company’s stock after purchasing an additional 330 shares during the quarter. Axxcess Wealth Management LLC’s holdings in CRISPR Therapeutics were worth $483,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Privium Fund Management B.V. lifted its stake in CRISPR Therapeutics by 11.0% during the third quarter. Privium Fund Management B.V. now owns 30,347 shares of the company’s stock worth $1,426,000 after purchasing an additional 3,000 shares during the period. Capital Advisors Inc. OK raised its stake in shares of CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after acquiring an additional 22,583 shares during the last quarter. Congress Asset Management Co. raised its stake in shares of CRISPR Therapeutics by 2.8% in the third quarter. Congress Asset Management Co. now owns 65,768 shares of the company’s stock valued at $3,090,000 after acquiring an additional 1,788 shares during the last quarter. HM Payson & Co. raised its stake in shares of CRISPR Therapeutics by 115.7% in the third quarter. HM Payson & Co. now owns 2,330 shares of the company’s stock valued at $109,000 after acquiring an additional 1,250 shares during the last quarter. Finally, Pinnacle Associates Ltd. bought a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $188,000. Institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

CRSP has been the subject of a number of research analyst reports. Chardan Capital cut their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They issued a “buy” rating and a $90.00 target price for the company. Barclays cut their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $74.94.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,382 shares of company stock valued at $1,917,679 over the last three months. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Stock Performance

CRSP opened at $49.79 on Thursday. The company has a fifty day moving average price of $47.80 and a two-hundred day moving average price of $52.12. CRISPR Therapeutics AG has a 52 week low of $43.42 and a 52 week high of $91.10. The firm has a market capitalization of $4.25 billion, a PE ratio of -17.59 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period last year, the firm posted ($1.41) earnings per share. Equities analysts forecast that CRISPR Therapeutics AG will post -5.2 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.